Article Text

Download PDFPDF

EPV037/#157 Incidence of cervical cancer and the HPV vaccine in the United States: are we seeing results of vaccination efforts?
  1. A Francoeur1,
  2. C-I Liao2,
  3. D Wong1,
  4. A Mann3,
  5. MA Caesar4,
  6. A Chan5,
  7. B Monk6,
  8. D Kapp7 and
  9. J Chan8
  1. 1University of California Los Angeles, Obstetrics and Gynecology, Los Angeles, USA
  2. 2Kaohsiung Veterans General Hospital, Obstetrics and Gynecology, Kaohsiung City, Taiwan
  3. 3Palo Alto Medical Foundation, Research Institute, Palo Alto, USA
  4. 4California Pacific Medical Center, Research Institute, San Francisco, USA
  5. 5Palo Alto Medical Foundation Research Intitute, Obstetrics and Gynecology, Palo Alto, USA
  6. 6Arizona Oncology, Gynecologic Oncology, Obstetrics and Gynecology, Phoenix, USA
  7. 7Stanford University School of Medicine, Department of Radiation Oncology, Stanford, USA
  8. 8California Pacific Medical Center, Obstetrics and Gynecology, San Francisco, USA


Objectives To determine the incidence and trends of cervical cancer in the United States in relation to the HPV vaccine.

Methods Data were obtained from the U.S. Cancer Statistics program from 2001–2017. SEER*Stat 8.3.8 and Joinpoint regression program were used to calculate incidence trends.

Results Over the last 17 years, cervical cancer incidence is decreasing at an average annual percent change (AAPC) of -1.03% (p<0.001). We performed a subset analysis of women who were 9–13 years old in 2006 when the HPV vaccine was approved, now 20–24 years old in 2017. In the pre-vaccine era (2001–2011), the incidence of cancer decreased 2.3% annually (p=0.038). of note, after the introduction of the vaccine (2011–2017), it decreased at 9.6% per year (p=0.002). In the pre-vaccine era (2001–2012), the incidence of new diagnoses of squamous cell carcinoma observed a decrease of 3.1% annually (p=0.004). However, in the post-vaccine era (2012–2017), there was an 11.8% decline in new cases per year (p=0.007). Although there is a decrease in older age groups, there is no difference in the trends pre and post vaccine era, particularly in the age groups who were not eligible for vaccination at that time.

Conclusions In our population analysis, our data suggest that the HPV vaccination may have decreased in incidence of cervical cancer in the younger cohort after its approval.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.